Key result
Trihexyphenidyl impairs motivated action vs placebo, mediated by medial frontal preparatory neural activity.
Why the study?
Acetylcholine modulates dopamine and motivation in animals, but whether muscarinic receptors mediate motivated action in humans is unclear, which is clinically relevant given anticholinergic use in Parkinson disease.
Does trihexyphenidyl blunt motivation effects on vigour and reaction times in healthy people?
RCT
Double-blind
Does trihexyphenidyl blunt motivation effects on vigour and reaction times in healthy people?
Muscarinic blockade with trihexyphenidyl impairs motivated action and blunts incentive-driven preparatory neural activity in healthy individuals.
Trihexyphenidyl may blunt motivated performance in treated patients; extends causal evidence for muscarinic cholinergic control of medial frontal preparatory activity.
Motivation depends on dopamine, but might be modulated by acetylcholine which influences dopamine release in the striatum, and amplifies motivation in animal studies. A corresponding effect in humans would be important clinically, since anticholinergic drugs are frequently used in Parkinson’s disease, a condition that can also disrupt motivation. Reward and dopamine make us more ready to respond, as indexed by reaction times (RT), and move faster, sometimes termed vigour. These effects may be controlled by preparatory processes that can be tracked using electroencephalography (EEG). We measured vigour in a placebo-controlled, double-blinded study of trihexyphenidyl (THP), a muscarinic antagonist, with an incentivised eye movement task and EEG. Participants responded faster and with greater vigour when incentives were high, but THP blunted these motivation effects, suggesting that muscarinic receptors facilitate invigoration by reward. Preparatory EEG build-up (contingent negative variation; CNV) was strengthened by high incentives and by muscarinic blockade, although THP reduced the incentive-effect. The amplitude of preparatory activity predicted both vigour and RT, although over distinct scalp regions; frontal activity predicted vigour, whereas a larger, earlier, central component predicted RT. The incentivisation of RT was partly mediated by the CNV, though vigour was not. Moreover, the CNV mediated the drug’s effect on dampening incentives, suggesting that muscarinic receptors underlie the motivational influence on this preparatory activity. Taken together, these findings show that a muscarinic blocker impairs motivated action in healthy people, and that medial frontal preparatory neural activity mediates this for RT.
No takes yet. Share an insight, caveat, or question.
Grogan et al. (2024) conducted an RCT in Healthy people. Trihexyphenidyl (THP) vs. Placebo was evaluated on Vigour and reaction times (RT). Trihexyphenidyl, a muscarinic blocker, impaired motivated action (reaction time and vigour) in healthy people, with medial frontal preparatory neural activity mediating this effect for reaction time.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: